Cart
sales@molnova.com
Entecavir hydrate
CAS No. 209216-23-9
Entecavir hydrate( Baraclude | BMS 200475 | SQ 34,676 )
Catalog No. M13277 CAS No. 209216-23-9
Entecavir, a new deoxyguanine nucleoside analogue, is a selective inhibitor of the replication of the hepatitis B virus (HBV).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 41 | In Stock |
|
| 10MG | 69 | In Stock |
|
| 25MG | 104 | In Stock |
|
| 50MG | 146 | In Stock |
|
| 100MG | 249 | In Stock |
|
| 200MG | 365 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEntecavir hydrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionEntecavir, a new deoxyguanine nucleoside analogue, is a selective inhibitor of the replication of the hepatitis B virus (HBV).
-
DescriptionEntecavir, a new deoxyguanine nucleoside analogue, is a selective inhibitor of the replication of the hepatitis B virus (HBV).
-
In Vitro——
-
In Vivo——
-
SynonymsBaraclude | BMS 200475 | SQ 34,676
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHBV( HepG2 cell)
-
Research AreaInfection
-
Indication——
Chemical Information
-
CAS Number209216-23-9
-
Formula Weight295.3
-
Molecular FormulaC12H15N5O3·H2O
-
Purity>98% (HPLC)
-
SolubilityDMSO: 59 mg/mL (199.8 mM)
-
SMILESC=C1[C@H](C[C@@H]([C@H]1CO)O)N2C=NC3=C2NC(=NC3=O)N.O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Levine S, et al. Antimicrob Agents ChemOthers, 2002, 46(8), 2525-2532.
molnova catalog
related products
-
Helioxanthin derivat...
Helioxanthin derivative 5-4-2 （Helioxanthin 5-4-2） is an analogue of helioxanthin that shows anti-HBV activity in vitro and can be used to study HBV.
-
CD437
CD437 is a specifc Retinoic Acid Receptor γ (RARγ) agonist.
-
Inarigivir ammonium
Inarigivir ammonium is a dinucleotide antiviral compound that significantly reduces HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir is an agonist of retinoic acid-inducible gene-I (RIG-I) that activates intracellular innate immunity.
